Quality oversight, regulatory perspective, and risk management in the changing vendor quality landscape are key topics of discussion at the FDA-NJPQCA Conference on May 23 in Kenilworth, New Jersey.
The theme of the event is “The New World of Pharmaceutical Quality” with a focus on vendor quality.
LBG’s Georgia Sloboda will join former colleagues and key industry leaders for a panel discussion. She will engage with the FDA and industry SMEs from AstraZeneca, Biohaven, Bristol Myers Sqibb, Hovione, WuXi Biologics, and Zentalis Pharmaceuticals to share her expertise and insight.
“The FDA-NJPQCA Conference offers a terrific opportunity to engage in an interactive session with industry and FDA experts on important topics to keep our pulse on the ever-changing landscape,” says Ms. Sloboda.
Ms. Sloboda leads the CMC segment offering for LBG. She has more than 30 years of experience in the biotechnology/pharmaceutical industry with an emphasis in the vaccines and oncology space. Her background includes experience in Quality Operations, Manufacturing Operations/Tech Transfer, Quality Systems and Compliance, Board of Health Inspection Management, External Supply, CDMO Oversight, and Regulatory Compliance.
